Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	structural constituent of synapse	SHANK2 PCLO CTNND2	1.88e-04	42	53	3	GO:0098918
GeneOntologyMolecularFunction	RNA polymerase II CTD heptapeptide repeat kinase activity	CDK12 CDK13	3.07e-04	10	53	2	GO:0008353
GeneOntologyMolecularFunction	structural constituent of postsynaptic density	SHANK2 CTNND2	3.74e-04	11	53	2	GO:0098919
GeneOntologyMolecularFunction	structural constituent of postsynaptic specialization	SHANK2 CTNND2	5.29e-04	13	53	2	GO:0098879
GeneOntologyMolecularFunction	protein tyrosine kinase activity	ERBB4 PEAK1 ALK EPHA10	5.93e-04	145	53	4	GO:0004713
GeneOntologyMolecularFunction	transmembrane receptor protein tyrosine kinase activity	ERBB4 ALK EPHA10	6.87e-04	65	53	3	GO:0004714
GeneOntologyMolecularFunction	protein kinase activity	ERBB4 MAST4 CDK12 CDK13 PEAK1 ALK EPHA10	9.92e-04	600	53	7	GO:0004672
GeneOntologyMolecularFunction	transmembrane receptor protein kinase activity	ERBB4 ALK EPHA10	1.50e-03	85	53	3	GO:0019199
GeneOntologyMolecularFunction	RNA polymerase II CTD heptapeptide repeat modifying activity	CDK12 CDK13	1.69e-03	23	53	2	GO:0140994
GeneOntologyMolecularFunction	protein domain specific binding	FZD8 WBP1 NCOA6 KIDINS220 SHANK2 SH3BP1 ARHGAP29 PLXNB3	2.03e-03	875	53	8	GO:0019904
GeneOntologyMolecularFunction	phosphotransferase activity, alcohol group as acceptor	ERBB4 MAST4 CDK12 CDK13 PEAK1 ALK EPHA10	2.57e-03	709	53	7	GO:0016773
GeneOntologyMolecularFunction	cyclin-dependent protein serine/threonine kinase activity	CDK12 CDK13	2.87e-03	30	53	2	GO:0004693
GeneOntologyMolecularFunction	cyclin-dependent protein kinase activity	CDK12 CDK13	2.87e-03	30	53	2	GO:0097472
GeneOntologyMolecularFunction	structural constituent of postsynapse	SHANK2 CTNND2	3.26e-03	32	53	2	GO:0099186
GeneOntologyMolecularFunction	cyclin binding	CDK12 CDK13	3.89e-03	35	53	2	GO:0030332
GeneOntologyMolecularFunction	kinase activity	ERBB4 MAST4 CDK12 CDK13 PEAK1 ALK EPHA10	3.89e-03	764	53	7	GO:0016301
GeneOntologyMolecularFunction	PDZ domain binding	FZD8 KIDINS220 ARHGAP29	4.27e-03	123	53	3	GO:0030165
GeneOntologyCellularComponent	cyclin/CDK positive transcription elongation factor complex	CDK12 CDK13	2.24e-04	9	53	2	GO:0008024
GeneOntologyCellularComponent	cyclin-dependent protein kinase holoenzyme complex	CCNL2 CDK12 CDK13	4.99e-04	61	53	3	GO:0000307
GeneOntologyCellularComponent	nuclear cyclin-dependent protein kinase holoenzyme complex	CDK12 CDK13	9.40e-04	18	53	2	GO:0019908
GeneOntologyCellularComponent	dendrite	CNNM4 ERBB4 SHANK2 ELFN1 PCLO TMEM151A CTNND2 EPHA10	1.34e-03	858	53	8	GO:0030425
GeneOntologyCellularComponent	dendritic tree	CNNM4 ERBB4 SHANK2 ELFN1 PCLO TMEM151A CTNND2 EPHA10	1.36e-03	860	53	8	GO:0097447
GeneOntologyCellularComponent	presynaptic active zone cytoplasmic component	PCLO PPFIA3	1.54e-03	23	53	2	GO:0098831
GeneOntologyCellularComponent	carboxy-terminal domain protein kinase complex	CDK12 CDK13	1.68e-03	24	53	2	GO:0032806
Domain	DUF3719	FAM149B1 FAM149A	7.90e-06	2	53	2	PF12516
Domain	DUF3719	FAM149B1 FAM149A	7.90e-06	2	53	2	IPR022194
Domain	SAM/pointed	KIDINS220 SHANK2 PPFIA3 EPHA10 GAREM1	2.00e-05	117	53	5	IPR013761
Domain	SAM_1	SHANK2 PPFIA3 EPHA10 GAREM1	4.11e-05	68	53	4	PF00536
Domain	Rho_GTPase_activation_prot	ARHGAP23 SH3BP1 ARHGAP29 PLXNB3	1.13e-04	88	53	4	IPR008936
Domain	Kinase-like_dom	ERBB4 MAST4 CDK12 CDK13 PEAK1 ALK EPHA10 PRDM2	1.34e-04	542	53	8	IPR011009
Domain	SAM_DOMAIN	SHANK2 PPFIA3 EPHA10 GAREM1	1.52e-04	95	53	4	PS50105
Domain	PROTEIN_KINASE_TYR	ERBB4 PEAK1 ALK EPHA10	1.65e-04	97	53	4	PS00109
Domain	SAM	SHANK2 PPFIA3 EPHA10 GAREM1	1.65e-04	97	53	4	IPR001660
Domain	Tyr_kinase_AS	ERBB4 PEAK1 ALK EPHA10	1.65e-04	97	53	4	IPR008266
Domain	PROTEIN_KINASE_ATP	ERBB4 MAST4 CDK12 CDK13 PEAK1 ALK EPHA10	3.00e-04	459	53	7	PS00107
Domain	Prot_kinase_dom	ERBB4 MAST4 CDK12 CDK13 PEAK1 ALK EPHA10	4.39e-04	489	53	7	IPR000719
Domain	PROTEIN_KINASE_DOM	ERBB4 MAST4 CDK12 CDK13 PEAK1 ALK EPHA10	4.61e-04	493	53	7	PS50011
Domain	Znf_CCCH	ZC3H13 RBM26 ZC3H12C	5.96e-04	58	53	3	IPR000571
Domain	ZF_C3H1	ZC3H13 RBM26 ZC3H12C	5.96e-04	58	53	3	PS50103
Domain	RhoGAP	ARHGAP23 SH3BP1 ARHGAP29	7.25e-04	62	53	3	SM00324
Domain	RhoGAP	ARHGAP23 SH3BP1 ARHGAP29	7.60e-04	63	53	3	PF00620
Domain	RHOGAP	ARHGAP23 SH3BP1 ARHGAP29	7.96e-04	64	53	3	PS50238
Domain	RhoGAP_dom	ARHGAP23 SH3BP1 ARHGAP29	7.96e-04	64	53	3	IPR000198
Domain	-	ARHGAP23 SH3BP1 ARHGAP29	7.96e-04	64	53	3	1.10.555.10
Domain	PDZ	MAST4 SHANK2 ARHGAP23 PCLO	8.84e-04	151	53	4	PS50106
Domain	PDZ	MAST4 SHANK2 ARHGAP23 PCLO	9.06e-04	152	53	4	IPR001478
Domain	TyrKc	ERBB4 ALK EPHA10	2.00e-03	88	53	3	SM00219
Domain	SAM	SHANK2 PPFIA3 EPHA10	2.00e-03	88	53	3	SM00454
Domain	Tyr_kinase_cat_dom	ERBB4 ALK EPHA10	2.00e-03	88	53	3	IPR020635
Domain	-	SHANK2 PPFIA3 EPHA10	3.39e-03	106	53	3	1.10.150.50
Domain	cNMP-bd-like	CNNM4 POPDC2	5.20e-03	38	53	2	IPR018490
Domain	-	ZC3H13 RBM26	5.75e-03	40	53	2	4.10.1000.10
Domain	Pkinase_Tyr	ERBB4 ALK EPHA10	5.86e-03	129	53	3	PF07714
Domain	Ser-Thr/Tyr_kinase_cat_dom	ERBB4 ALK EPHA10	7.06e-03	138	53	3	IPR001245
Domain	PDZ	MAST4 SHANK2 ARHGAP23	7.49e-03	141	53	3	PF00595
Domain	ZnF_C3H1	ZC3H13 RBM26	8.20e-03	48	53	2	SM00356
Domain	zf-CCCH	ZC3H13 RBM26	8.53e-03	49	53	2	PF00642
Domain	PDZ	MAST4 SHANK2 ARHGAP23	8.55e-03	148	53	3	SM00228
Domain	-	MAST4 SHANK2 ARHGAP23	8.87e-03	150	53	3	2.30.42.10
Domain	RmlC-like_jellyroll	CNNM4 POPDC2	9.22e-03	51	53	2	IPR014710
Pathway	REACTOME_RHO_GTPASE_CYCLE	KIDINS220 ARHGAP23 SH3BP1 ARHGAP29 EMD PEAK1 BAIAP2L2 SOS2	5.81e-06	439	33	8	MM15595
Pathway	REACTOME_RHO_GTPASE_CYCLE	KIDINS220 ARHGAP23 SH3BP1 ARHGAP29 EMD PEAK1 BAIAP2L2 SOS2	6.97e-06	450	33	8	M27078
Pathway	REACTOME_RAC1_GTPASE_CYCLE	ARHGAP23 SH3BP1 ARHGAP29 EMD SOS2	4.99e-05	175	33	5	MM15599
Pathway	REACTOME_RAC1_GTPASE_CYCLE	ARHGAP23 SH3BP1 ARHGAP29 EMD SOS2	6.33e-05	184	33	5	M41809
Pathway	REACTOME_SIGNALING_BY_RHO_GTPASES_MIRO_GTPASES_AND_RHOBTB3	KIDINS220 ARHGAP23 SH3BP1 ARHGAP29 EMD PEAK1 BAIAP2L2 SOS2	9.64e-05	649	33	8	MM15690
Pathway	REACTOME_SIGNALING_BY_RHO_GTPASES_MIRO_GTPASES_AND_RHOBTB3	KIDINS220 ARHGAP23 SH3BP1 ARHGAP29 EMD PEAK1 BAIAP2L2 SOS2	1.98e-04	720	33	8	M41838
Pathway	WP_MAPK_PATHWAY_IN_CONGENITAL_THYROID_CANCER	ALK SOS2	6.25e-04	16	33	2	M39882
Pathway	REACTOME_RORA_ACTIVATES_GENE_EXPRESSION	NCOA6 RORA	7.94e-04	18	33	2	M26942
Pubmed	A Global Analysis of the Receptor Tyrosine Kinase-Protein Phosphatase Interactome.	ERBB4 NADSYN1 SHANK2 CDK13 SRRM4 ARHGAP29 EMD ALK	2.71e-07	420	54	8	28065597
Pubmed	O-linked N-acetylglucosamine proteomics of postsynaptic density preparations using lectin weak affinity chromatography and mass spectrometry.	SHANK2 PCLO CTNND2	1.27e-06	14	54	3	16452088
Pubmed	Comprehensive identification of phosphorylation sites in postsynaptic density preparations.	SHANK2 PCLO PLEKHA6 PEAK1 PPFIA3 CTNND2	1.59e-06	231	54	6	16452087
Pubmed	Cdk12 and Cdk13 regulate axonal elongation through a common signaling pathway that modulates Cdk5 expression.	CDK12 CDK13	2.37e-06	2	54	2	24999027
Pubmed	Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer.	CDK12 CDK13	2.37e-06	2	54	2	35857807
Pubmed	Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium.	CDK12 CDK13	2.37e-06	2	54	2	30319007
Pubmed	Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing.	CDK12 CDK13	2.37e-06	2	54	2	25561469
Pubmed	CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1.	CDK12 CDK13	2.37e-06	2	54	2	20952539
Pubmed	E-cadherin interactome complexity and robustness resolved by quantitative proteomics.	KIDINS220 SHANK2 ARHGAP23 ARHGAP29 NAV2 PLEKHA6 EMD PEAK1	2.49e-06	565	54	8	25468996
Pubmed	Proteome-scale mapping of binding sites in the unstructured regions of the human proteome.	WBP1 NCOA6 LARP4B ERBB4 TMEM151A GAREM1 SOS2	4.51e-06	430	54	7	35044719
Pubmed	CDK13/CDC2L5 interacts with L-type cyclins and regulates alternative splicing.	CCNL2 CDK13	7.09e-06	3	54	2	17261272
Pubmed	BioID-Screening Identifies PEAK1 and SHP2 as Components of the ALK Proximitome in Neuroblastoma Cells.	PEAK1 ALK	7.09e-06	3	54	2	34273398
Pubmed	Aberrant expression of ALK and EZH2 in Merkel cell carcinoma.	ERBB4 ALK	7.09e-06	3	54	2	28359267
Pubmed	CDK12/13 promote splicing of proximal introns by enhancing the interaction between RNA polymerase II and the splicing factor SF3B1.	CDK12 CDK13	7.09e-06	3	54	2	37026485
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: IV. The complete nucleotide sequences of 500 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	CNNM4 LARP4B ARHGAP23 CDK13 FHDC1 PLEKHA6 PEAK1	1.10e-05	493	54	7	15368895
Pubmed	A probability-based approach for high-throughput protein phosphorylation analysis and site localization.	LARP4B CDK12 CDK13 ZC3H13 RBM26 NAV2 PLEKHA6	1.25e-05	503	54	7	16964243
Pubmed	The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes.	CDK12 CDK13	1.42e-05	4	54	2	22012619
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: III. the complete nucleotide sequences of 500 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	NCOA6 MAST4 CDK12 NBEAL2 SRRM4 NAV2 FAM149B1	1.73e-05	529	54	7	14621295
Pubmed	The TRIM9/TRIM67 neuronal interactome reveals novel activators of morphogenesis.	PCLO ZC3H12C PEAK1 PPFIA3 CTNND2	2.28e-05	218	54	5	33378226
Pubmed	Cyclin K-containing kinase complexes maintain self-renewal in murine embryonic stem cells.	CDK12 CDK13	2.36e-05	5	54	2	22547058
Pubmed	Refinement and discovery of new hotspots of copy-number variation associated with autism spectrum disorder.	ERBB4 CTNND2	2.36e-05	5	54	2	23375656
Pubmed	Neuron-specific protein network mapping of autism risk genes identifies shared biological mechanisms and disease-relevant pathologies.	LARP4B ERBB4 SHANK2 ELFN1 PCLO EMD PEAK1 PPFIA3 CTNND2	5.93e-05	1139	54	9	36417873
Pubmed	KCTD13-mediated ubiquitination and degradation of GluN1 regulates excitatory synaptic transmission and seizure susceptibility.	MGAT3 KIDINS220 CARMIL2 SHANK2 ARHGAP23 PCLO PLEKHA6 PEAK1 PPFIA3 CTNND2	6.18e-05	1431	54	10	37142655
Pubmed	Ligand binding to WW tandem domains of YAP2 transcriptional regulator is under negative cooperativity.	WBP1 ERBB4	1.29e-04	11	54	2	25283809
Pubmed	Meta-analysis of genome-wide association data of bipolar disorder and major depressive disorder.	PCLO LINC02694	1.29e-04	11	54	2	20351715
Pubmed	E3 ubiquitin ligase RNF123 targets lamin B1 and lamin-binding proteins.	PTPRN2 ZC3H13 PCLO EMD PPFIA3 PLXNB3 PRDM2	1.38e-04	736	54	7	29676528
Pubmed	Cyclin-dependent kinases: a family portrait.	CDK12 CDK13	1.55e-04	12	54	2	19884882
Pubmed	Systematic identification of SH3 domain-mediated human protein-protein interactions by peptide array target screening.	SHANK2 PTPRN2 PPFIA3 CSDC2 SOS2	1.59e-04	329	54	5	17474147
Pubmed	Shotgun sequencing of the human transcriptome with ORF expressed sequence tags.	NADSYN1 SHANK2 CDK12 NAV2 PLEKHA6 PRDM2	2.11e-04	552	54	6	10737800
Pubmed	The Functional Proximal Proteome of Oncogenic Ras Includes mTORC2.	KIDINS220 CARMIL2 NBEAL2 NAV2 PLEKHA6 PEAK1	2.48e-04	569	54	6	30639242
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	NCOA6 NADSYN1 SHANK2 CDK12 CDK13 NBEAL2 NAV2 GAREM1	2.88e-04	1105	54	8	35748872
Pubmed	Interactomes of Glycogen Synthase Kinase-3 Isoforms.	KIDINS220 MAST4 ARHGAP29 PEAK1	3.17e-04	209	54	4	36779422
Pubmed	Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder.	CNNM4 LINC02694	3.98e-04	19	54	2	18711365
Pubmed	Construction of expression-ready cDNA clones for KIAA genes: manual curation of 330 KIAA cDNA clones.	NCOA6 CDK12 NAV2 PPFIA3	4.19e-04	225	54	4	12168954
Pubmed	The RNA-mediated estrogen receptor α interactome of hormone-dependent human breast cancer cell nuclei.	USP30 LARP4B KIDINS220 SHANK2 CDK12 CDK13 RBM26 CHD1 CTNND2	4.58e-04	1497	54	9	31527615
Pubmed	Structural basis for endosomal trafficking of diverse transmembrane cargos by PX-FERM proteins.	ERBB4 PTPRN2 ALK	5.29e-04	101	54	3	23382219
Pubmed	Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4.	CNNM4 TMEM151A LINC02694	5.45e-04	102	54	3	21926972
Pubmed	Selected reaction monitoring mass spectrometry reveals the dynamics of signaling through the GRB2 adaptor.	PEAK1 GAREM1 SOS2	5.61e-04	103	54	3	21706016
Pubmed	The Nse5/6-like SIMC1-SLF2 complex localizes SMC5/6 to viral replication centers.	NCOA6 CDK12 ZC3H13 RBM26 CHD1 EMD ALK	6.59e-04	954	54	7	36373674
Pubmed	Laser capture microdissection and cDNA array analysis for identification of mouse KIAA/FLJ genes differentially expressed in the embryonic dorsal spinal cord.	NAV2 PPFIA3	8.10e-04	27	54	2	19026994
Pubmed	Role of the E3 ubiquitin ligase RNF157 as a novel downstream effector linking PI3K and MAPK signaling pathways to the cell cycle.	CHD1 EMD	8.72e-04	28	54	2	28655764
Pubmed	Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions.	ERBB4 CDK12 CHD1 ALK	8.98e-04	276	54	4	28319085
Pubmed	The insulin receptor substrate of 53 kDa (IRSp53) limits hippocampal synaptic plasticity.	SHANK2 CTNND2	9.35e-04	29	54	2	19208628
Pubmed	A human MAP kinase interactome.	KIAA1549L NAV2 PLEKHA6 GAREM1 SOS2	9.40e-04	486	54	5	20936779
Pubmed	Neurotransmitter release regulated by a MALS-liprin-alpha presynaptic complex.	ERBB4 PPFIA3	1.00e-03	30	54	2	16186258
Pubmed	Overlapping Activities of Two Neuronal Splicing Factors Switch the GABA Effect from Excitatory to Inhibitory by Regulating REST.	SHANK2 SRRM4 CTNND2	1.05e-03	128	54	3	30995482
Pubmed	The synaptic vesicle cycle.	PCLO PPFIA3	1.07e-03	31	54	2	15217342
Pubmed	miR-218 Promotes Dopaminergic Differentiation and Controls Neuron Excitability and Neurotransmitter Release through the Regulation of a Synaptic-Related Genes Network.	PCLO CTNND2	1.07e-03	31	54	2	37816598
Pubmed	A deep proteomics perspective on CRM1-mediated nuclear export and nucleocytoplasmic partitioning.	LARP4B SHANK2 RBM26 ARHGAP29 ZC3H12C PLEKHA6 GAREM1	1.08e-03	1038	54	7	26673895
Pubmed	Genome-wide association study of lung function decline in adults with and without asthma.	RORA CTNND2	1.14e-03	32	54	2	22424883
Pubmed	Robust phosphoproteomic profiling of tyrosine phosphorylation sites from human T cells using immobilized metal affinity chromatography and tandem mass spectrometry.	CDK13 ZC3H13 EMD	1.18e-03	133	54	3	15144186
Pubmed	The splicing regulator Rbfox2 is required for both cerebellar development and mature motor function.	LARP4B FAM149B1	1.21e-03	33	54	2	22357600
Pubmed	The DNA sequence of human chromosome 22.	MGAT3 SH3BP1 BAIAP2L2 CSDC2	1.22e-03	300	54	4	10591208
Cytoband	22q13.1	MGAT3 SH3BP1 BAIAP2L2	1.42e-04	85	54	3	22q13.1
Cytoband	17q12	GAS2L2 ARHGAP23 CDK12	2.23e-04	99	54	3	17q12
Cytoband	Ensembl 112 genes in cytogenetic band chr22q13	MGAT3 SH3BP1 BAIAP2L2 CSDC2	6.25e-04	330	54	4	chr22q13
Cytoband	Ensembl 112 genes in cytogenetic band chr17q12	GAS2L2 ARHGAP23 CDK12	7.36e-04	149	54	3	chr17q12
Cytoband	11q13.2	SHANK2 TMEM151A	1.42e-03	47	54	2	11q13.2
GeneFamily	Zinc fingers CCCH-type	ZC3H13 RBM26 ZC3H12C	3.17e-05	35	32	3	73
GeneFamily	Rho GTPase activating proteins\|BCH domain containing	ARHGAP23 SH3BP1 ARHGAP29	9.33e-05	50	32	3	721
GeneFamily	PDZ domain containing	MAST4 SHANK2 ARHGAP23 PCLO	1.44e-04	152	32	4	1220
GeneFamily	Sterile alpha motif domain containing	SHANK2 PPFIA3 EPHA10	4.99e-04	88	32	3	760
GeneFamily	Cyclin dependent kinases	CDK12 CDK13	9.61e-04	26	32	2	496
GeneFamily	Pleckstrin homology domain containing\|Rho guanine nucleotide exchange factors\|C2 domain containing	ARHGAP23 PLEKHA6 SOS2	5.67e-03	206	32	3	682
Coexpression	MANNO_MIDBRAIN_NEUROTYPES_HGABA	MAST4 SHANK2 KIAA1549L ARHGAP23 SRRM4 PCLO RBM26 RORA PLEKHA6 TMEM151A CTNND2 PRDM2	2.00e-06	1106	54	12	M39071
Coexpression	MANNO_MIDBRAIN_NEUROTYPES_HDA1	ERBB4 SHANK2 KIAA1549L ARHGAP23 SRRM4 RORA PLEKHA6 TMEM151A	2.44e-05	584	54	8	M39068
Coexpression	SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE_DN	ERBB4 MAST4 SHANK2 ARHGAP29	2.88e-05	85	54	4	M7012
Coexpression	GSE21063_CTRL_VS_ANTI_IGM_STIM_BCELL_NFATC1_KO_8H_UP	CCNL2 CDK12 NBEAL2 CHD1 ALK	4.73e-05	192	54	5	M8272
Coexpression	ZHONG_PFC_C3_MICROGLIA	MAST4 SHANK2 KIAA1549L SRRM4 PCLO EPHA10 CSDC2	6.18e-05	488	54	7	M39104
Coexpression	LAKE_ADULT_KIDNEY_C3_PROXIMAL_TUBULE_EPITHELIAL_CELLS_S1_S2	MAST4 ZC3H13 PCLO RORA PLEKHA6	9.20e-05	221	54	5	M39222
ToppCell	Children_(3_yrs)-Epithelial-club_cell-D046\|Children_(3_yrs) / Lineage, Cell type, age group and donor	ERBB4 MAST4 SHANK2 C12orf56 NAV2 GAREM1 FAM149A	2.21e-09	180	54	7	b509c7d6bdfba672065fb722874bdc68de72ba1c
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Epithelial\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ERBB4 MAST4 SHANK2 PCLO RORA PLEKHA6 GAREM1	3.58e-09	193	54	7	3866667dd221612589ae50f5c52f73a183a49ce6
ToppCell	Control-Multiplet\|Control / Disease state, Lineage and Cell class	ERBB4 MAST4 SHANK2 ARHGAP29 NAV2 RORA FHDC1	3.84e-09	195	54	7	618900c80bea09d46dad3f741bd1bff8bf0a64ee
ToppCell	Control-Multiplet-Multiplet\|Control / Disease state, Lineage and Cell class	ERBB4 MAST4 SHANK2 ARHGAP29 NAV2 RORA FHDC1	3.84e-09	195	54	7	06ac685855e14e4dd2cbe6d0e73f894f2eeff91f
ToppCell	Control-Epithelial_cells-Airway_club\|Control / group, cell type (main and fine annotations)	ERBB4 MAST4 SHANK2 NAV2 GAREM1 FAM149A	8.58e-08	181	54	6	c755d23dd9aabc717dc73e2b3fa99a1f751e6507
ToppCell	Adult-Epithelial-club_cell-D231\|Adult / Lineage, Cell type, age group and donor	ERBB4 MAST4 SHANK2 RORA GAREM1 FAM149A	1.04e-07	187	54	6	ee59d7d3de5879738ff0b9c3ea5e4847fb48cb86
ToppCell	Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_2-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	ERBB4 MAST4 PCLO FHDC1 GAREM1 FAM149A	1.22e-07	192	54	6	cc9911e182a289779a2612bc213daae5607689e7
ToppCell	Epithelial-club_cell\|World / Lineage, Cell type, age group and donor	ERBB4 MAST4 SHANK2 NAV2 GAREM1 FAM149A	1.25e-07	193	54	6	2bdd09004fa433550958ec42ba4b06271a4aaf7c
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	ERBB4 MAST4 SHANK2 ARHGAP29 PLEKHA6 GAREM1	1.29e-07	194	54	6	7002937e8903e037332a215d00fbc7c7843b33f2
ToppCell	Fetal_29-31_weeks-Epithelial-club_cell-D062\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	ERBB4 MAST4 SHANK2 NAV2 FAM149A	1.56e-06	162	54	5	5c9bc3c3857a99d8a3caf359a7eb279ce9cc1c81
ToppCell	Fetal_29-31_weeks-Epithelial-club_cell-D088\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	ERBB4 MAST4 SHANK2 NAV2 FAM149A	2.34e-06	176	54	5	3bbac5c2397535631fce8fa98f6ddb4fe0260351
ToppCell	TCGA-Adrenal-Primary_Tumor-Pheochromocytoma-Pheochromocytoma-1\|TCGA-Adrenal / Sample_Type by Project: Shred V9	KIDINS220 PTPRN2 PCLO PLEKHA6 ALK	2.55e-06	179	54	5	431e1b29015ec817f778499106d24b19cfc825ae
ToppCell	COVID-19-kidney-Distal_Epi_Doublet_(PCT)\|COVID-19 / Disease (COVID-19 only), tissue and cell type	ERBB4 SHANK2 PCLO PLEKHA6 FAM149A	2.76e-06	182	54	5	9d67717a6e13bcb54c1297a3e4e3abf4e51628a3
ToppCell	Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_2/Club-like_(AT2/Club-like)-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	ERBB4 MAST4 SHANK2 GAREM1 FAM149A	2.91e-06	184	54	5	102105ae1a5ef6d42a43f6d9b00f12ed0690ddb7
ToppCell	Adult-Epithelial-alveolar_epithelial_cell_type_2/Club-like_(AT2/Club-like)\|Adult / Lineage, Cell type, age group and donor	ERBB4 MAST4 SHANK2 GAREM1 FAM149A	2.99e-06	185	54	5	673f0c688ae6984bc8027df2da335787924f4137
ToppCell	Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_2/Club-like_(AT2/Club-like)\|Children_(3_yrs) / Lineage, Cell type, age group and donor	ERBB4 MAST4 SHANK2 GAREM1 FAM149A	2.99e-06	185	54	5	98b8ee42b89d97e4c9db01740e0c193503c68f2c
ToppCell	COVID-19-Epithelial_cells-Airway_club\|COVID-19 / group, cell type (main and fine annotations)	ERBB4 MAST4 SHANK2 NAV2 FAM149A	2.99e-06	185	54	5	cfe6fd73d817e173fe803bc1683c291d9bcb8608
ToppCell	Epithelial-alveolar_epithelial_cell_type_1\|World / Lineage, Cell type, age group and donor	SHANK2 NBEAL2 NAV2 ZC3H12C CTNND2	3.07e-06	186	54	5	09d95daa3387a4814cffaa4b798cc2810c3759d0
ToppCell	Fetal_29-31_weeks-Epithelial-lung_neuroendocrine_cell_(PNEC)\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	PTPRN2 SRRM4 PCLO CTNND2 FAM149A	3.07e-06	186	54	5	b45cce768e4bf91da194fd9660cab7520dfb15ac
ToppCell	Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_1-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	SHANK2 NBEAL2 NAV2 ZC3H12C CTNND2	3.15e-06	187	54	5	d4b0afd9b92c47c8aa348bbd1af7eb54c3d478f2
ToppCell	Adult-Epithelial-alveolar_epithelial_cell_type_2-D175\|Adult / Lineage, Cell type, age group and donor	ERBB4 MAST4 PCLO FHDC1 GAREM1	3.24e-06	188	54	5	ec38def1fdbb34ed9b30244806975bd5a4370164
ToppCell	Fetal_29-31_weeks-Epithelial-lung_neuroendocrine_cell_(PNEC)-D150\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	PTPRN2 SRRM4 PCLO CTNND2 FAM149A	3.24e-06	188	54	5	c4c3b21ab723b0e9beff9ec84f8d68485f771528
ToppCell	PCW_07-8.5-Epithelial-Epithelial_airway-epi_proximal_progenitor1_(6)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	ERBB4 SHANK2 PCLO CTNND2 FAM149A	3.32e-06	189	54	5	7659c7bbd58ee959a159294fb8d17317bbcc5681
ToppCell	Fetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_1/2_(AT1/AT2-like)\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	LARP4B ERBB4 MAST4 SHANK2 NAV2	3.49e-06	191	54	5	ca5669bd6f4a17471acae3eb229f845cc2e08efa
ToppCell	LAM-Epithelial-AT1\|Epithelial / Condition, Lineage and Cell class	MGAT3 NBEAL2 ARHGAP29 NAV2 PEAK1	3.49e-06	191	54	5	3457e15d1e9b36a78363d46b320c4ec46b40290a
ToppCell	Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_2\|Children_(3_yrs) / Lineage, Cell type, age group and donor	ERBB4 MAST4 SHANK2 FHDC1 GAREM1	3.49e-06	191	54	5	a0332a4ef629510fb313ec119195c44a3f704a80
ToppCell	Children_(3_yrs)-Epithelial-club_cell\|Children_(3_yrs) / Lineage, Cell type, age group and donor	ERBB4 MAST4 SHANK2 GAREM1 FAM149A	3.49e-06	191	54	5	23776c7302cead3881b39127398f3b3e0d27885e
ToppCell	COVID-19-lung-AT2\|lung / Disease (COVID-19 only), tissue and cell type	ERBB4 MAST4 SHANK2 PCLO FHDC1	3.49e-06	191	54	5	276455a64c2c3503d5048615762eb2ee37f0ac70
ToppCell	Control-Multiplet-Multiplet\|World / Disease state, Lineage and Cell class	ERBB4 MAST4 SHANK2 ARHGAP29 FHDC1	3.59e-06	192	54	5	1bfd022d5b87cf8a5d5069f559339a553a52a0a2
ToppCell	Adult-Epithelial\|Adult / Lineage, Cell type, age group and donor	ERBB4 MAST4 SHANK2 NAV2 GAREM1	3.59e-06	192	54	5	efb962a5fd3b9bdfd8cf8d13c435e29c8271713e
ToppCell	Epithelial\|World / Lineage, Cell type, age group and donor	ERBB4 MAST4 SHANK2 NAV2 GAREM1	3.59e-06	192	54	5	499e8893afea5e6d3371e0bd018f7e86a524d669
ToppCell	PCW_07-8.5-Epithelial-Epithelial_neuroendo-epi_NE_progenitor_(7)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	ERBB4 SHANK2 PCLO CTNND2 FAM149A	3.59e-06	192	54	5	b99f8236ef4ccdc75c02abea381cae6453205f6f
ToppCell	Epithelial-alveolar_epithelial_cell_type_2\|World / Lineage, Cell type, age group and donor	ERBB4 MAST4 SHANK2 FHDC1 GAREM1	3.59e-06	192	54	5	58c3737be7acce39fd2b91d70d6d7b2bbaa4f710
ToppCell	facs-Brain_Non-Myeloid-Cortex-3m-Neuronal-neuron\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SHANK2 KIAA1549L PTPRN2 PPFIA3 EPHA10	3.68e-06	193	54	5	461919ab422bc9d1fcff7a3a4757c75239041d7e
ToppCell	facs-Brain_Non-Myeloid-Cortex-3m-Neuronal-nan\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SHANK2 KIAA1549L PTPRN2 PPFIA3 EPHA10	3.68e-06	193	54	5	0dd810ad900d3e586551622b2c1de39d76fd6a7f
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ERBB4 MAST4 SHANK2 PCLO GAREM1	3.68e-06	193	54	5	82e8a4c40299ffcdfd5a0da711bb9de6fb8a2eaa
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	ERBB4 MAST4 SHANK2 PCLO GAREM1	3.77e-06	194	54	5	5eaaa81f4b2535f983c424aaef00077089526a5c
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Epithelial\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	ERBB4 MAST4 SHANK2 PCLO GAREM1	3.87e-06	195	54	5	6477e6e7be5bd8eb99119a12ae16334ccddecd43
ToppCell	Children_(3_yrs)-Epithelial-club_cell-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	ERBB4 MAST4 SHANK2 CTNND2 FAM149A	3.87e-06	195	54	5	dccc32fcf772e2504de7f663ef0a5bd8e23e92fc
ToppCell	Control-Epithelial\|Control / Disease state, Lineage and Cell class	ERBB4 MAST4 SHANK2 NAV2 FHDC1	3.87e-06	195	54	5	1798c3b89b1b5ff4f5777d2b9f52dc81cdad28fa
ToppCell	Bronchial-NucSeq\|Bronchial / Cell types per location group and 10X technology with lineage, and cell group designations	ERBB4 SHANK2 NAV2 RORA GAREM1	3.96e-06	196	54	5	ab53c742866945545a92e2e61850d63c80d9a2a6
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	SHANK2 KIAA1549L PTPRN2 SRRM4 PCLO	3.96e-06	196	54	5	676c56b44ac29f7baecb62f49bb8597cc74c0a88
ToppCell	Somatosensory_Cortex_(S1)-Neuronal\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	SHANK2 KIAA1549L PTPRN2 SRRM4 PCLO	4.17e-06	198	54	5	c01091ef18e096d792ea2a7a715764a5b215355f
ToppCell	primary_auditory_cortex_(A1C)-Neuronal\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	SHANK2 KIAA1549L PTPRN2 SRRM4 PCLO	4.17e-06	198	54	5	6d18b45eda4014759e6dd282d78ffd28df8a6044
ToppCell	Bronchial-NucSeq-Epithelial-Epi_alveolar-AT2\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	ERBB4 MAST4 SHANK2 FHDC1 GAREM1	4.17e-06	198	54	5	f948391296c261c473d339069a6d0f20ccd6f38f
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Neuronal\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	SHANK2 KIAA1549L PTPRN2 SRRM4 PCLO	4.17e-06	198	54	5	0ff30edfd3c133a42e8cb96e1631a1143215f808
ToppCell	Fetal_29-31_weeks-Epithelial-club_cell\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	ERBB4 MAST4 SHANK2 NAV2 FAM149A	4.17e-06	198	54	5	5fc25b008a4d8d6bec83923a16f64dd9e1ff1f2d
ToppCell	Primary_Motor_Cortex_(M1)-Neuronal\|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	SHANK2 KIAA1549L PTPRN2 SRRM4 PCLO	4.17e-06	198	54	5	4ca5ff320905ab4ff60ed90a5522227c782142a6
ToppCell	Tracheal-NucSeq-Epithelial\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	ERBB4 SHANK2 PTPRN2 PCLO GAREM1	4.37e-06	200	54	5	d3af0a706baf66e3f32e67b17dcfc31e5b32ce0e
ToppCell	Neuronal\|World / cells hierarchy compared to all cells using T-Statistic	SHANK2 KIAA1549L PTPRN2 SRRM4 PCLO	4.37e-06	200	54	5	48d801219bc771d6c7e151dc88ca4c179988de85
ToppCell	Fetal_brain-fetalBrain_Zhong_nature-GW23-Neuronal-GABAergic_neurons\|GW23 / Sample Type, Dataset, Time_group, and Cell type.	ERBB4 ARHGAP23 PTPRN2 ELFN1 SRRM4	4.37e-06	200	54	5	c6bbd33bca86ac7a76a7ba704b3e141237d04549
ToppCell	E18.5-samps-Mesenchymal-Myofibroblast-myofibroblast_-_mature_-_B\|E18.5-samps / Age Group, Lineage, Cell class and subclass	NADSYN1 CARMIL2 KIAA1549L CSDC2	2.31e-05	137	54	4	b553958e7e6dcd887d860e34d3983cbb85cefaa6
ToppCell	Fetal_29-31_weeks-Epithelial-lung_neuroendocrine_cell_(PNEC)-D088\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	PTPRN2 SRRM4 PCLO CTNND2	4.14e-05	159	54	4	7747cef94c55144fddcd024a7495318357f1351b
ToppCell	Adult-Epithelial-alveolar_epithelial_cell_type_1/2_(AT1/AT2-like)\|Adult / Lineage, Cell type, age group and donor	ERBB4 MAST4 SHANK2 FAM149A	4.56e-05	163	54	4	e819a1d6d28290854aa0672b3a18fa9e293d8f23
ToppCell	frontal_cortex-Neuronal-GABAergic_neuron-Lamp5-Lamp5_Lsp1\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	KIDINS220 RORA ALK BAIAP2L2	4.56e-05	163	54	4	bba830a302919c8b33f914a8839877fc21dd28a0
ToppCell	primary_visual_cortex-Neuronal-GABAergic_neuron-Lamp5\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	ERBB4 RORA ALK BAIAP2L2	4.56e-05	163	54	4	8d17f44faf0549fe71a9a45f811f50d767275414
ToppCell	frontal_cortex-Neuronal-GABAergic_neuron-Lamp5\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	ERBB4 RORA ALK BAIAP2L2	4.67e-05	164	54	4	08819970174a3eb4eee8e1e675075828665b845e
ToppCell	PCW_07-8.5-Neuronal-Neuronal_SCP-neuro_proliferating_SCP3_(1)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	ERBB4 GAS2L2 ALK PLXNB3	5.01e-05	167	54	4	49b19159c62d33d65ed1e59a148c11ae902fd41c
ToppCell	Posterior_cortex-Neuronal-Inhibitory\|Posterior_cortex / BrainAtlas - Mouse McCarroll V32	ERBB4 ELFN1 ALK BAIAP2L2	5.01e-05	167	54	4	9a84f45345c75f2c8ff38a04245aadee2a26a240
ToppCell	Control\|World / group, cell type (main and fine annotations)	ERBB4 SHANK2 PTPRN2 NAV2	5.13e-05	168	54	4	a3511faf2cd2c2b9c8363c8b99da3f3609c43ed6
ToppCell	Frontal_cortex-Neuronal-Inhibitory\|Frontal_cortex / BrainAtlas - Mouse McCarroll V32	ERBB4 ELFN1 ALK CSDC2	5.25e-05	169	54	4	78eb70dd916724e476eabccf18fb7fcec4210308
ToppCell	Adult-Epithelial-alveolar_epithelial_cell_type_2/Club-like_(AT2/Club-like)-D231\|Adult / Lineage, Cell type, age group and donor	ERBB4 MAST4 GAREM1 FAM149A	5.37e-05	170	54	4	269dee5abca9f6aa079f116f0d8f1d198604d9d4
ToppCell	Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_1/2_(AT1/AT2-like)-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	LARP4B ERBB4 MAST4 SHANK2	5.37e-05	170	54	4	a2c738e441ced90eeeb1fcc6ca3269b918aaa298
ToppCell	COVID-19-kidney-Distal_Epi_Doublet_(PCT)\|kidney / Disease (COVID-19 only), tissue and cell type	ERBB4 PCLO PLEKHA6 FAM149A	6.14e-05	176	54	4	36f77d878a53b30465b0dea8333a3865dba75613
ToppCell	COVID-19-kidney-Epi_(Mes)\|COVID-19 / Disease (COVID-19 only), tissue and cell type	ERBB4 SHANK2 ARHGAP29 PLEKHA6	6.42e-05	178	54	4	544379f5a6145429762258d426b876bb36c112f5
ToppCell	Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_2/Club-like_(AT2/Club-like)-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	ERBB4 MAST4 SHANK2 FAM149A	6.42e-05	178	54	4	f5ed4a6e3eb8056b1be1fb311021710c95bdf888
ToppCell	Adult-Epithelial-club_cell-D122\|Adult / Lineage, Cell type, age group and donor	ERBB4 MAST4 SHANK2 C12orf56	6.42e-05	178	54	4	35a2e3ba98b6f857dbb79cf8ddb4846ddcda6c17
ToppCell	Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_1/2_(AT1/AT2-like)\|Children_(3_yrs) / Lineage, Cell type, age group and donor	ERBB4 MAST4 SHANK2 NAV2	6.56e-05	179	54	4	cb38b54261a7af5ee3347e64c8aa880a77ed0763
ToppCell	Fetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_2/Club-like_(AT2/Club-like)-D150\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	ERBB4 MAST4 SHANK2 FAM149A	6.56e-05	179	54	4	815b959ce8721c5ded70c0ca6e318dafc691746e
ToppCell	Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_1-D046\|Children_(3_yrs) / Lineage, Cell type, age group and donor	SHANK2 NAV2 ZC3H12C CTNND2	6.56e-05	179	54	4	4f6ca313b78aa93557937a046c44dcf8bcc9963c
ToppCell	PCW_13-14-Neuronal-Neuronal_postreplicative-neuro_neuronal_(6)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	SRRM4 TMEM151A ALK EPHA10	6.56e-05	179	54	4	af0b54c9ea0b6e4210f22dbb6e88ecd3276a5f86
ToppCell	Control-Epithelial_cells-AT2\|Control / group, cell type (main and fine annotations)	ERBB4 MAST4 FHDC1 GAREM1	6.70e-05	180	54	4	198b19e7910b4a8cc7e820c525ab357c7f99f578
ToppCell	PCW_07-8.5-Neuronal-Neuronal_SCP-neuro_SCP_(0)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	FZD8 ERBB4 ALK PLXNB3	6.85e-05	181	54	4	fad7ba168f541ac9d04edebc206f191e48bb7e99
ToppCell	droplet-Lung-nan-3m-Epithelial\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ELFN1 FHDC1 CTNND2 GAREM1	7.00e-05	182	54	4	cfba75c1ffc39ac76db9e8e27394731942882b30
ToppCell	Epithelial-lung_neuroendocrine_cell_(PNEC)\|World / Lineage, Cell type, age group and donor	PTPRN2 SRRM4 PCLO CTNND2	7.00e-05	182	54	4	57bf4ffb304324e2e392e196336a530d9f78fe0d
ToppCell	Children_(3_yrs)-Epithelial-club_cell-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	ERBB4 SHANK2 GAREM1 FAM149A	7.00e-05	182	54	4	215c303df42f13597b2c7a95cb157c6bc7aca9a1
ToppCell	frontal_cortex-Neuronal-GABAergic_neuron\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	ERBB4 ELFN1 ALK CSDC2	7.00e-05	182	54	4	f2a1784ffcba9b27132e0db21e574cbd8a0a6418
ToppCell	droplet-Lung-nan-3m-Epithelial-type_II_pneumocyte\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ELFN1 FHDC1 CTNND2 GAREM1	7.00e-05	182	54	4	7e7c7a26460d3003cdf0c0ffb96208a566aa09a7
ToppCell	droplet-Lung-nan-3m-Epithelial-Alveolar_Epithelial_Type_2\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ELFN1 FHDC1 CTNND2 GAREM1	7.00e-05	182	54	4	d836bfdc298ecd3558a973e393a329eb8bd59d79
ToppCell	Globus_pallidus-Neuronal-Inhibitory\|Globus_pallidus / BrainAtlas - Mouse McCarroll V32	ELFN1 SRRM4 ALK EPHA10	7.00e-05	182	54	4	04ccfa951eaa31fed6d140edb6c702d49363c5fa
ToppCell	COVID-19-lung-AT1\|lung / Disease (COVID-19 only), tissue and cell type	SHANK2 NBEAL2 NAV2 CTNND2	7.15e-05	183	54	4	942530449e9c6583705eeb8f6f12621daea57252
ToppCell	Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_2-D046\|Children_(3_yrs) / Lineage, Cell type, age group and donor	ERBB4 MAST4 SHANK2 GAREM1	7.15e-05	183	54	4	6847c1252d6bb105524f812658112517fd351eab
ToppCell	COPD-Epithelial-ATII\|World / Disease state, Lineage and Cell class	ERBB4 MAST4 SHANK2 FHDC1	7.15e-05	183	54	4	8e9aab4eeec2e282c2cab9bfca6dbf40d660c7b9
ToppCell	wk_15-18-Epithelial-Proximal_epithelial-intermediate_neuroendocrine\|wk_15-18 / Celltypes from embryonic and fetal-stage human lung	SRRM4 PCLO TMEM151A CTNND2	7.30e-05	184	54	4	9e5f98f9113e5e38bdadba6d9d2c346177fb35fe
ToppCell	nucseq-Epithelial-Epithelial_Alveolar-AT1-AT1\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	SHANK2 NAV2 PEAK1 CTNND2	7.30e-05	184	54	4	57c792e6e2fedba25d3350ffe649fd74750b579d
ToppCell	Fetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_1-D062\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	SHANK2 NBEAL2 NAV2 ZC3H12C	7.30e-05	184	54	4	29c95b814a0b1ad8734ed68b77df29c08594e5ec
ToppCell	nucseq-Epithelial-Epithelial_Alveolar-AT1\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	SHANK2 NAV2 PEAK1 CTNND2	7.30e-05	184	54	4	d7bd0f0c607bade67c99e9fb3578a570298bf926
ToppCell	Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_1\|Children_(3_yrs) / Lineage, Cell type, age group and donor	SHANK2 NBEAL2 NAV2 CTNND2	7.45e-05	185	54	4	1c222f7285d6e3dae0354dc7e853ddc0ea55e63e
ToppCell	367C-Endothelial_cells-Endothelial-B_(Artery)-\|Endothelial_cells / Donor, Lineage, Cell class and subclass (all cells)	ERBB4 MAST4 PLEKHA6 POPDC2	7.45e-05	185	54	4	b57dae20c21f984edd2acee4344d86f033108ebf
ToppCell	367C-Endothelial_cells-Endothelial-B_(Artery)\|Endothelial_cells / Donor, Lineage, Cell class and subclass (all cells)	ERBB4 MAST4 PLEKHA6 POPDC2	7.45e-05	185	54	4	d3b054d203e575c1bb5455aa7a2e551a0957a760
ToppCell	Adult-Epithelial-alveolar_epithelial_cell_type_1-D175\|Adult / Lineage, Cell type, age group and donor	SHANK2 ZC3H12C PEAK1 CTNND2	7.45e-05	185	54	4	32b4e68e551d435a732f253f6ad83408c759a642
ToppCell	5'-GW_trimst-2-SmallIntestine-Neuronal-neurons_B-Branch_B2_(eMN)\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	SRRM4 PCLO TMEM151A CSDC2	7.61e-05	186	54	4	24b23880d4ff8fb4a23e2012d5890b9e2fcf7283
ToppCell	Fetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_2/Club-like_(AT2/Club-like)\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	ERBB4 MAST4 SHANK2 FAM149A	7.61e-05	186	54	4	2ea5ff14861e5f91d0e6a5767c403a24045d715c
ToppCell	Control-Epithelial-Club\|World / Disease state, Lineage and Cell class	ERBB4 MAST4 SHANK2 NAV2	7.61e-05	186	54	4	9798428691408e17ff2af2fe2d1b345f074d67e4
ToppCell	COPD-Epithelial-Club\|World / Disease state, Lineage and Cell class	ERBB4 MAST4 SHANK2 NAV2	7.61e-05	186	54	4	3006f4ab1eaf1eb34c10ca9f7c869603d2d25744
ToppCell	COVID-19-kidney\|COVID-19 / Disease (COVID-19 only), tissue and cell type	ERBB4 SHANK2 PCLO PLEKHA6	7.77e-05	187	54	4	d23aae9419d460b78b1d4092d7acd9108a47cfbe
ToppCell	Fetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_1-D150\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	MGAT3 SHANK2 NBEAL2 CTNND2	7.77e-05	187	54	4	4ae7465174e0295d2c3b614b321a3b2f514dd22a
ToppCell	Adult-Epithelial-alveolar_epithelial_cell_type_1\|Adult / Lineage, Cell type, age group and donor	SHANK2 NBEAL2 PEAK1 CTNND2	7.77e-05	187	54	4	77f78aec946bc6bd85c29aee9ca978ce49f853a3
ToppCell	facs-Brain_Non-Myeloid-Hippocampus-24m-Neuronal-neuron\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PTPRN2 PCLO PPFIA3 EPHA10	7.77e-05	187	54	4	e04a84989d624378141042768383b9c846901f2d
ToppCell	Epithelial-alveolar_epithelial_cell_type_2/Club-like_(AT2/Club-like)\|World / Lineage, Cell type, age group and donor	ERBB4 MAST4 SHANK2 FAM149A	7.77e-05	187	54	4	81cc8435b2704a9a8287b3f54acaae0f11dd4ac7
Drug	semduramicin	NCOA6 SHANK2	5.32e-06	2	53	2	CID000071327
Drug	Ricinine [524-40-3]; Down 200; 24.4uM; HL60; HT_HG-U133A	MGAT3 CDK13 RBM26 FAM149B1 PRDM2 SOS2	5.66e-06	193	53	6	2505_DN
Drug	LY 294002; Up 200; 10uM; HL60; HT_HG-U133A	LARP4B C16orf95 PCLO FAM149B1 PRDM2 SOS2	5.83e-06	194	53	6	6195_UP
Drug	Aminopurine, 6-benzyl [1214-39-7]; Up 200; 17.8uM; MCF7; HT_HG-U133A	ERBB4 KIDINS220 C16orf95 ZC3H13 RORA CSDC2	6.55e-06	198	53	6	2313_UP
Drug	Meprylcaine hydrochloride [956-03-6]; Up 200; 14.8uM; MCF7; HT_HG-U133A	ERBB4 CDK13 RBM26 FAM149B1 PEAK1 FAM149A	6.74e-06	199	53	6	3544_UP
Drug	2-propylpentanoic acid; Up 200; 50uM; HL60; HT_HG-U133A	LARP4B SHANK2 PCLO RORA PLEKHA6 PRDM2	6.94e-06	200	53	6	6181_UP
Drug	irinotecan HCl; Down 200; 100uM; PC3; HT_HG-U133A	LARP4B MAST4 CDK13 NAV2 SOS2	4.83e-05	171	53	5	7535_DN
Drug	Phenoxybenzamine hydrochloride [63-92-3]; Down 200; 11.8uM; MCF7; HT_HG-U133A	MAST4 SHANK2 PPFIA3 CTNND2 SOS2	6.67e-05	183	53	5	5613_DN
Drug	LY 294002; Up 200; 10uM; MCF7; HT_HG-U133A	CNNM4 KIDINS220 C16orf95 PCLO ARHGAP29	7.02e-05	185	53	5	6945_UP
Drug	Methiothepin maleate [19728-88-2]; Up 200; 8.4uM; MCF7; HT_HG-U133A	SHANK2 NBEAL2 NAV2 ALK SOS2	7.77e-05	189	53	5	5413_UP
Drug	pioglitazone HCl; Down 200; 10uM; PC3; HT_HG-U133A	FZD8 SHANK2 PTPRN2 CDK13 SOS2	8.36e-05	192	53	5	5930_DN
Drug	Decamethonium bromide [541-22-0]; Up 200; 9.6uM; HL60; HT_HG-U133A	KIDINS220 PTPRN2 C16orf95 ALK SOS2	8.57e-05	193	53	5	2933_UP
Drug	Bromperidol [10457-90-6]; Down 200; 9.6uM; MCF7; HT_HG-U133A	KIDINS220 PPFIA3 CTNND2 GAREM1 SOS2	8.78e-05	194	53	5	7457_DN
Drug	15d-PGJ2; Down 200; 10uM; MCF7; HT_HG-U133A	MAST4 SHANK2 C16orf95 PPFIA3 SOS2	9.00e-05	195	53	5	5228_DN
Drug	Sulfadimethoxine [122-11-2]; Down 200; 12.8uM; PC3; HT_HG-U133A	CNNM4 CDK13 PLEKHA6 PPFIA3 GAREM1	9.00e-05	195	53	5	7400_DN
Drug	felodipine; Down 200; 10uM; MCF7; HT_HG-U133A_EA	CNNM4 CDK13 CTNND2 PRDM2 SOS2	9.22e-05	196	53	5	848_DN
Drug	Amiprilose hydrochloride [60414-06-4]; Up 200; 11.8uM; PC3; HT_HG-U133A	PTPRN2 CDK13 PPFIA3 ALK SOS2	9.22e-05	196	53	5	4000_UP
Drug	Dipivefrin hydrochloride [64019-93-8]; Down 200; 10.4uM; MCF7; HT_HG-U133A	CDK13 PPFIA3 CTNND2 PRDM2 SOS2	9.22e-05	196	53	5	6766_DN
Drug	clozapine; Up 200; 10uM; MCF7; HT_HG-U133A	FZD8 KIDINS220 NBEAL2 RBM26 SOS2	9.22e-05	196	53	5	5226_UP
Drug	Solanine alpha [20562-02-1]; Up 200; 4.6uM; PC3; HT_HG-U133A	ZC3H13 RBM26 PEAK1 CTNND2 PRDM2	9.22e-05	196	53	5	4087_UP
Drug	Bacitracin [1405-87-4]; Down 200; 2.8uM; MCF7; HT_HG-U133A	C16orf95 NBEAL2 FAM149B1 PPFIA3 CTNND2	9.22e-05	196	53	5	7448_DN
Drug	sulfasalazine; Down 200; 100uM; MCF7; HG-U133A	LARP4B ZC3H13 PPFIA3 CTNND2 SOS2	9.22e-05	196	53	5	204_DN
Drug	Dydrogesterone [152-62-5]; Up 200; 12.8uM; HL60; HT_HG-U133A	CNNM4 C16orf95 ZC3H13 ALK CSDC2	9.44e-05	197	53	5	2156_UP
Drug	estradiol; Up 200; 0.01uM; PC3; HT_HG-U133A	PTPRN2 CDK13 POPDC2 ALK GAREM1	9.44e-05	197	53	5	5960_UP
Drug	Trimethoprim [738-70-5]; Up 200; 13.8uM; MCF7; HT_HG-U133A	KIDINS220 SHANK2 CDK13 RORA ALK	9.44e-05	197	53	5	2307_UP
Drug	Conessine [546-06-5]; Down 200; 11.2uM; MCF7; HT_HG-U133A	MAST4 EMD FAM149B1 PPFIA3 CTNND2	9.44e-05	197	53	5	4777_DN
Drug	Pentolinium bitartrate [52-62-0]; Up 200; 7.4uM; PC3; HT_HG-U133A	LARP4B PTPRN2 RBM26 CTNND2 SOS2	9.67e-05	198	53	5	7375_UP
Drug	Oxaprozin [21256-18-8]; Up 200; 13.6uM; PC3; HT_HG-U133A	PTPRN2 C16orf95 CDK13 RBM26 SOS2	9.67e-05	198	53	5	4530_UP
Drug	Norgestrel-(-)-D [797-63-7]; Up 200; 12.8uM; MCF7; HT_HG-U133A	MGAT3 KIDINS220 MAST4 PPFIA3 SOS2	9.67e-05	198	53	5	3406_UP
Drug	fluphenazine dihydrochloride; Up 200; 10uM; HL60; HT_HG-U133A	MGAT3 KIDINS220 C16orf95 PCLO PRDM2	9.67e-05	198	53	5	6196_UP
Drug	Mexiletine hydrochloride [5370-01-4]; Up 200; 18.6uM; PC3; HT_HG-U133A	MGAT3 SH3BP1 ALK PRDM2 SOS2	9.67e-05	198	53	5	3781_UP
Drug	Piperidolate hydrochloride [129-77-1]; Up 200; 11.2uM; HL60; HT_HG-U133A	MGAT3 C16orf95 SH3BP1 PRDM2 GAREM1	9.67e-05	198	53	5	6129_UP
Drug	Fluoxetine hydrochloride [59333-67-4]; Up 200; 11.6uM; HL60; HT_HG-U133A	CNNM4 ZC3H13 FAM149B1 PPFIA3 SOS2	9.67e-05	198	53	5	2453_UP
Drug	Mecamylamine hydrochloride [826-39-1]; Up 200; 19.6uM; MCF7; HT_HG-U133A	MGAT3 MAST4 C16orf95 PPFIA3 SOS2	9.67e-05	198	53	5	7023_UP
Drug	Piperine [94-62-2]; Up 200; 14uM; MCF7; HT_HG-U133A	CDK13 ZC3H13 PCLO FAM149B1 SOS2	9.67e-05	198	53	5	4830_UP
Drug	estradiol, USP; Down 200; 0.01uM; MCF7; HG-U133A	SHANK2 CDK13 NBEAL2 PPFIA3 PRDM2	9.67e-05	198	53	5	121_DN
Drug	Dioxybenzone [131-53-3]; Up 200; 16.4uM; HL60; HT_HG-U133A	PTPRN2 NAV2 PLEKHA6 ALK GAREM1	9.90e-05	199	53	5	3101_UP
Drug	Acebutolol hydrochloride [34381-68-5]; Up 200; 10.8uM; PC3; HT_HG-U133A	KIDINS220 C16orf95 RORA PRDM2 SOS2	9.90e-05	199	53	5	6631_UP
Drug	Bretylium tosylate [61-75-6]; Down 200; 9.6uM; PC3; HT_HG-U133A	MAST4 SHANK2 KIAA1549L ALK SOS2	9.90e-05	199	53	5	6674_DN
Drug	Meptazinol hydrochloride [59263-76-2]; Up 200; 14.8uM; MCF7; HT_HG-U133A	CNNM4 KIDINS220 ZC3H13 PCLO SOS2	9.90e-05	199	53	5	4774_UP
Drug	Fenbendazole [43210-67-9]; Up 200; 13.4uM; PC3; HT_HG-U133A	MGAT3 MAST4 SHANK2 RORA FAM149A	9.90e-05	199	53	5	3805_UP
Drug	Homosalate [118-56-9]; Up 200; 15.2uM; PC3; HT_HG-U133A	CNNM4 C16orf95 CDK13 RBM26 SOS2	9.90e-05	199	53	5	4533_UP
Drug	Cyclopentolate hydrochloride [5870-29-1]; Up 200; 12.2uM; HL60; HT_HG-U133A	ERBB4 SHANK2 C16orf95 SH3BP1 FAM149A	9.90e-05	199	53	5	6132_UP
Drug	Ticlopidine hydrochloride [53885-35-1]; Down 200; 13.4uM; MCF7; HT_HG-U133A	KIDINS220 C16orf95 CTNND2 PRDM2 SOS2	9.90e-05	199	53	5	1475_DN
Drug	Amphotericin B [1397-89-3]; Down 200; 4.4uM; PC3; HT_HG-U133A	CNNM4 KIDINS220 SHANK2 PLEKHA6 SOS2	1.01e-04	200	53	5	6303_DN
Drug	Nitrofural [59-87-0]; Up 200; 20.2uM; HL60; HT_HG-U133A	CNNM4 PTPRN2 NBEAL2 ZC3H13 SOS2	1.01e-04	200	53	5	2459_UP
Drug	butylurethane	NCOA6 SHANK2	4.75e-04	14	53	2	CID000011577
Drug	Camptothecine (S,+) [7689-03-4]; Down 200; 11.4uM; MCF7; HT_HG-U133A	LARP4B CHD1 PRDM2 SOS2	8.52e-04	182	53	4	3887_DN
Drug	irinotecan HCl; Down 200; 100uM; MCF7; HT_HG-U133A	LARP4B CDK12 CHD1 PRDM2	8.70e-04	183	53	4	7498_DN
Drug	Raloxifene hydrochloride [82640-04-8]; Up 200; 7.8uM; MCF7; HT_HG-U133A	PLEKHA6 CTNND2 PRDM2 SOS2	8.70e-04	183	53	4	3480_UP
Drug	Zardaverine [101975-10-4]; Up 200; 15uM; PC3; HT_HG-U133A	CDK13 POPDC2 CTNND2 FAM149A	9.42e-04	187	53	4	4209_UP
Drug	Thonzonium bromide [553-08-2]; Up 200; 6.8uM; MCF7; HT_HG-U133A	FZD8 SHANK2 RORA PRDM2	9.42e-04	187	53	4	5678_UP
Drug	Clioquinol [130-26-7]; Up 200; 13uM; HL60; HT_HG-U133A	MGAT3 SHANK2 PTPRN2 PCLO	9.80e-04	189	53	4	3084_UP
Drug	Tiapride hydrochloride [51012-33-0]; Down 200; 11uM; MCF7; HT_HG-U133A	LARP4B CDK13 PLEKHA6 PPFIA3	1.04e-03	192	53	4	2292_DN
Drug	Betamethasone [378-44-9]; Up 200; 10.2uM; PC3; HT_HG-U133A	ZC3H13 NAV2 CTNND2 ALK	1.04e-03	192	53	4	6728_UP
Drug	Prednisolone [50-24-8]; Up 200; 11uM; PC3; HT_HG-U133A	CNNM4 MAST4 C16orf95 NAV2	1.04e-03	192	53	4	5101_UP
Drug	Rapamycin; Up 200; 0.1uM; MCF7; HT_HG-U133A	MAST4 C16orf95 NAV2 FAM149B1	1.04e-03	192	53	4	6958_UP
Drug	AG-013608 [351320-38-2]; Down 200; 10uM; PC3; HT_HG-U133A	LARP4B KIDINS220 RORA CTNND2	1.06e-03	193	53	4	6400_DN
Drug	Carbamazepine [298-46-4]; Down 200; 17uM; PC3; HT_HG-U133A	CNNM4 SHANK2 C16orf95 PPFIA3	1.06e-03	193	53	4	1805_DN
Drug	Clenbuterol hydrochloride [21898-19-1]; Down 200; 12.8uM; PC3; HT_HG-U133A	RBM26 NAV2 PLEKHA6 SOS2	1.06e-03	193	53	4	4671_DN
Drug	Guanfacine hydrochloride [29110-48-3]; Down 200; 14.2uM; MCF7; HT_HG-U133A	C16orf95 ZC3H13 PLEKHA6 CTNND2	1.06e-03	193	53	4	5256_DN
Drug	Gly-His-Lys acetate salt; Down 200; 1uM; MCF7; HT_HG-U133A	KIDINS220 C16orf95 PPFIA3 PRDM2	1.08e-03	194	53	4	6575_DN
Drug	Retrorsine [480-54-6]; Down 200; 11.4uM; MCF7; HT_HG-U133A	PLEKHA6 PPFIA3 GAREM1 SOS2	1.08e-03	194	53	4	2784_DN
Drug	Nadolol [42200-33-9]; Up 200; 13uM; MCF7; HT_HG-U133A	SHANK2 FAM149B1 ALK SOS2	1.08e-03	194	53	4	4139_UP
Drug	Orphenadrine hydrochloride [341-69-5]; Up 200; 13uM; PC3; HT_HG-U133A	CNNM4 C16orf95 PEAK1 CTNND2	1.08e-03	194	53	4	4537_UP
Drug	Roxithromycin [80214-83-1]; Down 200; 4.8uM; PC3; HT_HG-U133A	CDK13 NBEAL2 CTNND2 GAREM1	1.08e-03	194	53	4	4192_DN
Drug	Sulfamethazine sodium salt [1981-58-4]; Up 200; 13.4uM; MCF7; HT_HG-U133A	MAST4 CDK13 PPFIA3 ALK	1.08e-03	194	53	4	3422_UP
Drug	Fludrocortisone acetate [514-36-3]; Up 200; 9.4uM; PC3; HT_HG-U133A	MGAT3 KIAA1549L ZC3H13 SOS2	1.08e-03	194	53	4	3785_UP
Drug	Ergocryptine-alpha [511-09-1]; Up 200; 7uM; PC3; HT_HG-U133A	MGAT3 PTPRN2 CTNND2 SOS2	1.08e-03	194	53	4	4552_UP
Drug	Halcinonide [3093-35-4]; Up 200; 8.8uM; PC3; HT_HG-U133A	LARP4B NAV2 ALK GAREM1	1.08e-03	194	53	4	7379_UP
Drug	Ethisterone [434-03-7]; Up 200; 12.8uM; PC3; HT_HG-U133A	MAST4 SH3BP1 ALK SOS2	1.08e-03	194	53	4	3783_UP
Drug	radicicol; Down 200; 0.1uM; PC3; HT_HG-U133A	KIDINS220 MAST4 ZC3H13 SOS2	1.08e-03	194	53	4	5952_DN
Drug	Tolbutamide [64-77-7]; Up 200; 14.8uM; PC3; HT_HG-U133A	MGAT3 SHANK2 CDK13 CTNND2	1.10e-03	195	53	4	3804_UP
Drug	radicicol, diheterospora chlamydosporia; Down 200; 0.1uM; MCF7; HT_HG-U133A_EA	LARP4B MAST4 NBEAL2 GAREM1	1.10e-03	195	53	4	999_DN
Drug	Megestrol acetate [595-33-5]; Up 200; 10.4uM; HL60; HT_HG-U133A	MGAT3 PTPRN2 ZC3H13 GAREM1	1.10e-03	195	53	4	3091_UP
Drug	Suloctidil [54063-56-8]; Down 200; 11.8uM; MCF7; HT_HG-U133A	CNNM4 MAST4 SHANK2 PPFIA3	1.10e-03	195	53	4	5021_DN
Drug	Aminopurine, 6-benzyl [1214-39-7]; Down 200; 17.8uM; MCF7; HT_HG-U133A	SHANK2 PCLO PRDM2 SOS2	1.10e-03	195	53	4	4748_DN
Drug	Hecogenin [467-55-0]; Down 200; 9.2uM; MCF7; HT_HG-U133A	NBEAL2 FAM149B1 PPFIA3 SOS2	1.10e-03	195	53	4	3457_DN
Drug	Pramoxine hydrochloride [637-58-1]; Up 200; 12.2uM; MCF7; HT_HG-U133A	MGAT3 MAST4 ZC3H13 ALK	1.10e-03	195	53	4	4368_UP
Drug	Flupentixol dihydrochloride cis-(Z) [2413-38-9]; Up 200; 7.8uM; MCF7; HT_HG-U133A	KIDINS220 MAST4 CTNND2 SOS2	1.10e-03	195	53	4	2643_UP
Drug	haloperidol; Up 200; 10uM; MCF7; HT_HG-U133A_EA	MGAT3 CDK13 PPFIA3 SOS2	1.10e-03	195	53	4	983_UP
Drug	Chicago sky blue 6B [2610-05-1]; Up 200; 4uM; MCF7; HT_HG-U133A	C16orf95 PPFIA3 FAM149A SOS2	1.10e-03	195	53	4	4971_UP
Drug	Ofloxacin [82419-36-1]; Up 200; 11uM; MCF7; HT_HG-U133A	CDK13 RBM26 PRDM2 SOS2	1.10e-03	195	53	4	4696_UP
Drug	Trichostatin A, Streptomyces sp.; Up 200; 0.1uM; HL60; HT_HG-U133A	PTPRN2 PCLO CTNND2 GAREM1	1.12e-03	196	53	4	6171_UP
Drug	Scopolamin-N-oxide hydrobromide [6106-81-6]; Down 200; 10uM; PC3; HT_HG-U133A	CNNM4 KIAA1549L NBEAL2 PLEKHA6	1.12e-03	196	53	4	2099_DN
Drug	Benperidol [2062-84-2]; Down 200; 10.4uM; PC3; HT_HG-U133A	CNNM4 NBEAL2 PPFIA3 SOS2	1.12e-03	196	53	4	4196_DN
Drug	Cephalothin sodium salt [58-71-9]; Up 200; 9.6uM; PC3; HT_HG-U133A	CNNM4 MAST4 SHANK2 ALK	1.12e-03	196	53	4	4482_UP
Drug	Neomycin sulfate [1405-10-3]; Down 200; 4.2uM; MCF7; HT_HG-U133A	KIDINS220 C16orf95 PPFIA3 SOS2	1.12e-03	196	53	4	2229_DN
Drug	Parbendazole [14255-87-9]; Down 200; 16.2uM; MCF7; HT_HG-U133A	MAST4 CDK13 PCLO PPFIA3	1.12e-03	196	53	4	3881_DN
Drug	Pancuronium bromide [15500-66-0]; Down 200; 5.4uM; MCF7; HT_HG-U133A	MAST4 C16orf95 FAM149B1 PPFIA3	1.12e-03	196	53	4	7329_DN
Drug	(S)-(-)-Cycloserine [339-72-0]; Up 200; 39.2uM; PC3; HT_HG-U133A	CNNM4 CDK13 CTNND2 PRDM2	1.12e-03	196	53	4	4524_UP
Drug	Nizatidine [76963-41-2]; Up 200; 12uM; PC3; HT_HG-U133A	NBEAL2 PPFIA3 ALK SOS2	1.12e-03	196	53	4	6305_UP
Drug	Pyrithyldione [77-04-3]; Down 200; 24uM; MCF7; HT_HG-U133A	MAST4 CDK13 PPFIA3 SOS2	1.12e-03	196	53	4	3482_DN
Drug	PNU-0230031 [267429-39-0]; Up 200; 1uM; PC3; HT_HG-U133A	LARP4B ZC3H13 CTNND2 SOS2	1.12e-03	196	53	4	4291_UP
Drug	Trimethobenzamide hydrochloride [554-92-7]; Down 200; 9.4uM; PC3; HT_HG-U133A	CNNM4 C16orf95 PPFIA3 PRDM2	1.12e-03	196	53	4	4100_DN
Drug	Cefsulodin sodium salt [52152-93-9]; Down 200; 7.2uM; MCF7; HT_HG-U133A	CDK13 NBEAL2 PLEKHA6 SOS2	1.12e-03	196	53	4	4148_DN
Drug	Nicardipine hydrochloride [54527-84-3]; Up 200; 7.8uM; MCF7; HT_HG-U133A	KIDINS220 SHANK2 PCLO SOS2	1.12e-03	196	53	4	5397_UP
Drug	Adenosine 5'-monophosphate monohydrate [18422-05-4]; Down 200; 11uM; PC3; HT_HG-U133A	LARP4B SHANK2 CTNND2 PRDM2	1.12e-03	196	53	4	6760_DN
Drug	Retinoic acid [302-79-4]; Up 200; 13.4uM; PC3; HT_HG-U133A	LARP4B RBM26 SH3BP1 ALK	1.12e-03	196	53	4	5767_UP
Drug	Conessine [546-06-5]; Up 200; 11.2uM; PC3; HT_HG-U133A	MAST4 CTNND2 ALK FAM149A	1.12e-03	196	53	4	4191_UP
Disease	urate measurement, bone density	LARP4B ERBB4 KIDINS220 MAST4 PTPRN2 PEAK1 CTNND2	1.02e-04	619	52	7	EFO_0003923, EFO_0004531
Disease	obsessive-compulsive disorder, attention deficit hyperactivity disorder, Tourette syndrome, unipolar depression, bipolar disorder, autism spectrum disorder, schizophrenia, anorexia nervosa	CNNM4 PCLO RORA LINC02694	4.30e-04	200	52	4	EFO_0003756, EFO_0003761, EFO_0003888, EFO_0004242, EFO_0004895, MONDO_0004985, MONDO_0005090, MONDO_0005351
Disease	neuroticism measurement, cognitive function measurement	ERBB4 PCLO NAV2 RORA TMEM151A CTNND2	4.67e-04	566	52	6	EFO_0007660, EFO_0008354
Disease	white matter microstructure measurement	MAST4 C16orf95 NAV2 LINC02694 BAIAP2L2	6.13e-04	390	52	5	EFO_0005674
Disease	Hepatitis	ARHGAP29 NAV2	6.88e-04	22	52	2	HP_0012115
Disease	Hypermetropia	NADSYN1 PTPRN2 CDK12	8.06e-04	103	52	3	HP_0000540
Disease	non-alcoholic fatty liver disease severity measurement	C16orf95 LINC02694	1.12e-03	28	52	2	EFO_0008421
Disease	creatinine measurement, glomerular filtration rate	NCOA6 LARP4B CDK12	1.17e-03	117	52	3	EFO_0004518, EFO_0005208
Disease	blood urea nitrogen measurement	LARP4B CDK12 RORA PLEKHA6 LINC02694	1.19e-03	452	52	5	EFO_0004741
Disease	puberty onset measurement	NCOA6 RORA PRDM2	1.41e-03	125	52	3	EFO_0005677
Disease	Squamous cell carcinoma of lung	ERBB4 MAST4	1.46e-03	32	52	2	C0149782
Disease	Bipolar Disorder	ERBB4 SHANK2 PCLO RORA LINC02694	1.50e-03	477	52	5	C0005586
Disease	chronic rhinosinusitis	GAS2L2 PTPRN2	1.65e-03	34	52	2	EFO_1000024
Disease	Vertigo	MAST4 PEAK1 PRDM2	1.91e-03	139	52	3	HP_0002321
Disease	bipolar I disorder	CNNM4 SHANK2 LINC02694	1.99e-03	141	52	3	EFO_0009963
Disease	Cutaneous Melanoma	ERBB4 ALK	2.39e-03	41	52	2	C0151779
Disease	response to antihypertensive drug	ERBB4 ALK	2.39e-03	41	52	2	EFO_0005405
Disease	autism spectrum disorder (implicated_via_orthology)	SHANK2 CHD1 CTNND2	2.46e-03	152	52	3	DOID:0060041 (implicated_via_orthology)
Disease	childhood gender nonconformity	KIAA1549L NAV2	2.63e-03	43	52	2	EFO_0020103
Disease	suicide behaviour measurement	RORA CTNND2	2.63e-03	43	52	2	EFO_0006882
Disease	spleen volume	PLEKHA6 LINC02694	2.63e-03	43	52	2	EFO_0600047
Disease	unipolar depression, bipolar disorder	CNNM4 PCLO LINC02694	2.65e-03	156	52	3	EFO_0003761, MONDO_0004985
Disease	vitamin D measurement	NADSYN1 SHANK2 TMEM151A PEAK1	2.91e-03	336	52	4	EFO_0004631
Disease	disorder of pharynx	CARMIL2 GAS2L2	3.00e-03	46	52	2	MONDO_0020592
Disease	neuropathic pain	C16orf95 RORA	3.13e-03	47	52	2	EFO_0005762
Disease	Hepatic fibrosis	ERBB4 KIAA1549L	3.40e-03	49	52	2	HP_0001395

Protein segments in the cluster

Peptide	Gene	Start	Entry
PPPIYTSRARIDSNR	ERBB4	1031	Q15303
QSSTRSPSPYSRRQR	CDK12	286	Q9NYV4
SPSPYSRRQRSVSPY	CDK12	291	Q9NYV4
TRPRPRDLAYSQLSP	ELFN1	741	P0C7U0
SSPDPAGRSRPRYTR	CARMIL2	1156	Q6F5E8
ARRQSRRSPASPSPA	SH3BP1	631	Q9Y3L3
RSPLDQRSPYGSRSP	CHD1	1676	O14646
PRSPSPYSRRRSPSY	CDK13	356	Q14004
DRQRPYSSSRTPSIS	CTNND2	1046	Q9UQB3
SRRLNHSPPQSSSRY	RBM26	121	Q5T8P6
YLRRPEASSPARPSK	PTPRN2	116	Q92932
PSSPSYRPPNTRRSR	FHDC1	526	Q9C0D6
RSQRSSYTRLSKDPP	KIDINS220	1736	Q9ULH0
NGSSARRPPRYLLSA	MGAT3	141	Q09327
SRRSPAPLLSSPYSR	FAM149A	66	A5PLN7
QLRGRPPSSYSRSLP	PPFIA3	496	O75145
AASPLTSLRQYPPRS	LARP4B	396	Q92615
TSLRQYPPRSRNPSK	LARP4B	401	Q92615
RRSLPRTPSASSLYS	BAIAP2L2	291	Q6UXY1
KPYSSGSRSRPSSRP	PCLO	4281	Q9Y6V0
RPCNPEPSLYRTSAR	PLXNB3	876	Q9ULL4
TRADLPRIPFRSPYS	PEAK1	1621	Q9H792
PARQQTRSPSPTLSY	GAREM1	556	Q9H706
YPRSRYPQSSPSRLP	KIAA1549L	1766	Q6ZVL6
RPPSAPRDLQYSLSR	EPHA10	336	Q5JZY3
TSRPKTPNRASPRPY	NCOA6	1206	Q14686
RRSSDSYPLAPVRAP	ARHGAP29	1141	Q52LW3
LPRRPPRAARSYSCS	FAM189B	391	P81408
YNRTDLTTAAPSPPR	FZD8	151	Q9H461
SRSRSDSPPRQAPRS	CCNL2	421	Q96S94
YTSSDRRLRPPTPSS	GAS2L2	326	Q8NHY3
PTHSLSPRSPTPSYR	MAST4	1301	O15021
SSSRPPTRTSYRLLQ	C16orf95	136	Q9H693
YETQRRRLSPPSSSA	EMD	41	P50402
PSPLPTKRTRTYSAT	CSDC2	46	Q9Y534
SRFKRRTSSPPSSPQ	PRDM2	731	Q13029
YTVQSTRRRNPPPRT	FAM149B1	411	Q96BN6
PSPRVPRRCYVLSSS	SOS2	1266	Q07890
RLRPPSQGYLSSRSP	NBEAL2	2041	Q6ZNJ1
SSRTNLQYRSLPRPS	NAV2	1206	Q8IVL1
RRSVSSNSLPPARPS	TMEM151A	381	Q8N4L1
SYVPGPRSRSPSLNR	SHANK2	466	Q9UPX8
SFLRETRPRPSQPSS	ALK	1206	Q9UM73
QGAFRPLPSPSRRSS	C12orf56	191	Q8IXR9
ASSPSYLTVPRRSPL	LINC02694	121	Q8NAA6
PTPLSRSASLSYPDR	CNNM4	656	Q6P4Q7
YSPVRSPSARFERLP	PLEKHA6	471	Q9Y2H5
RTAQRPRPFSSSPRS	nan	46	P0C879
PRPFSSSPRSASGRL	nan	51	P0C879
PPAPVRRQSYSSTSR	RORA	41	P35398
PRKTYAPPARASTRA	ARHGAP23	191	Q9P227
RSPNPRASPRYTQSR	SRRM4	406	A7MD48
TTNFPAPPTRARLSR	POPDC2	316	Q9HBU9
YRRSPPSARNPLSTS	USP30	456	Q70CQ3
YSNLSLSGPRSPERR	ZC3H12C	596	Q9C0D7
NYLSLPRPRASSPSN	PRR30	101	Q53SZ7
PASTPPSCRYRRLTG	WBP1	196	Q96G27
SPSPRRKRTPSPSYQ	ZC3H13	346	Q5T200
RKRTPSPSYQRTLTP	ZC3H13	351	Q5T200
SPSYQRTLTPPLRRS	ZC3H13	356	Q5T200
SSRNLAASRASPYPR	NADSYN1	286	Q6IA69